Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
BH3-only protein BIM: An emerging target in chemotherapy
BH3-only proteins constitute major proportion of pro-apoptotic members of B-cell lymphoma
2 (Bcl-2) family of apoptotic regulatory proteins and participate in embryonic development …
2 (Bcl-2) family of apoptotic regulatory proteins and participate in embryonic development …
MicroRNA-124 suppresses proliferation and glycolysis in non–small cell lung cancer cells by targeting AKT–GLUT1/HKII
X Zhao, C Lu, W Chu, B Zhang, Q Zhen… - Tumor …, 2017 - journals.sagepub.com
Non–small cell lung cancer accounts for 85% of all types of lung cancer and is the leading
cause of worldwide cancer-associated mortalities. MiR-124 is epigenetically silenced in …
cause of worldwide cancer-associated mortalities. MiR-124 is epigenetically silenced in …
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: Meta-analysis of 153 cohorts with 15,713 patients: Meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
Tumor drug concentration and phosphoproteomic profiles after two weeks of treatment with sunitinib in patients with newly diagnosed glioblastoma
ME Van Linde, M Labots, CG Brahm, KE Hovinga… - Clinical Cancer …, 2022 - AACR
Purpose: Tyrosine kinase inhibitors (TKI) have poor efficacy in patients with glioblastoma
(GBM). Here, we studied whether this is predominantly due to restricted blood–brain barrier …
(GBM). Here, we studied whether this is predominantly due to restricted blood–brain barrier …
Pulsatile Erlotinib in EGFR-positive non–small-cell lung cancer patients with leptomeningeal and brain metastases: review of the literature
J How, J Mann, AN Laczniak, MQ Baggstrom - Clinical Lung Cancer, 2017 - Elsevier
Patients with epidermal growth factor receptor (EGFR)-positive (EGFR+) non–small-cell lung
cancer (NSCLC) show improved response rates when treated with tyrosine kinase inhibitors …
cancer (NSCLC) show improved response rates when treated with tyrosine kinase inhibitors …
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Background Afatinib is an oral irreversible epidermal growth factor receptor (EGFR) tyrosine-
kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) …
kinase inhibitor (TKI) indicated in first-line treatment of advanced EGFR-mutant (EGFRm+) …
Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis
P Xing, Y Mu, X Hao, Y Wang, J Li - Clinical and Translational Oncology, 2019 - Springer
Objectives Central nervous system (CNS) metastases are very common in patients with non-
small-cell lung cancer (NSCLC). We aimed to explore the clinical impact of osimertinib, a …
small-cell lung cancer (NSCLC). We aimed to explore the clinical impact of osimertinib, a …
[HTML][HTML] Preliminary evaluation of the potential role of β‑elemene in reversing erlotinib‑resistant human NSCLC A549/ER cells
L Lin, L Li, X Chen, B Zeng, T Lin - Oncology letters, 2018 - spandidos-publications.com
Abstract β‑elemene (β‑ELE) is a natural compound extracted from Curcuma zedoaria
Roscoe that has shown promise as a novel anticancer drug to treat malignant tumors …
Roscoe that has shown promise as a novel anticancer drug to treat malignant tumors …
[HTML][HTML] A multicenter double-blind phase II study of metformin with gefitinib as first-line therapy of locally advanced non–small-cell lung cancer
K Li, L Li, P Zhang, J Kang, Y Wang, H Chen, Y He - Clinical Lung Cancer, 2017 - Elsevier
We present the rationale and study design of the CGMT (combined gefitinib and metformin
therapy) trial (www. ClinicalTrials. gov Identifier: NCT01864681), which is aimed at treating …
therapy) trial (www. ClinicalTrials. gov Identifier: NCT01864681), which is aimed at treating …